About Biodexa Pharmaceuticals
Biodexa Pharmaceuticals is a company based in Cardiff (United Kingdom) founded in 2000.. Biodexa Pharmaceuticals has raised $6.79 million across 1 funding round. Biodexa Pharmaceuticals offers products and services including eRapa, Tolimidone, and MTX110. Biodexa Pharmaceuticals operates in a competitive market with competitors including Modifi Bio, OncoSynergy, Plex Pharmaceuticals, Flag Therapeutics and Purposeful, among others.
- Headquarter Cardiff, United Kingdom
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Biodexa Pharmaceuticals Plc
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$6.79 M (USD)
in 1 rounds
-
Latest Funding Round
$6.79 M (USD), Series A
Dec 21, 2023
-
Investors
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Biodexa Pharmaceuticals
Biodexa Pharmaceuticals offers a comprehensive portfolio of products and services, including eRapa, Tolimidone, and MTX110. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Oral formulation for treating familial adenomatous polyposis.
Inhibitor for managing type 1 diabetes symptoms.
Treatment for primary and metastatic brain cancers.
Funding Insights of Biodexa Pharmaceuticals
Biodexa Pharmaceuticals has successfully raised a total of $6.79M through 1 strategic funding round. The most recent funding activity was a Series A round of $6.79 million completed in December 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 1
- Last Round Series A — $6.8M
-
First Round
First Round
(21 Dec 2023)
- Investors Count Investors Count
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec, 2023 | Amount | Series A - Biodexa Pharmaceuticals | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investments & Acquisitions by Biodexa Pharmaceuticals
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Biodexa Pharmaceuticals
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Biodexa Pharmaceuticals Comparisons
Competitors of Biodexa Pharmaceuticals
Biodexa Pharmaceuticals operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Modifi Bio, OncoSynergy, Plex Pharmaceuticals, Flag Therapeutics and Purposeful, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Developer of therapeutics for the treatment of cancer
|
|
| domain | founded_year | HQ Location |
Resistance mechanism inhibitors for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Discovering small molecules for diseases caused by protein misfolding such as Parkinson's.
|
|
| domain | founded_year | HQ Location |
Small molecule therapeutics for difficult-to-treat cancers are developed.
|
|
| domain | founded_year | HQ Location |
Purposeful is engaged in discovering treatments for rare diseases.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Biodexa Pharmaceuticals
Frequently Asked Questions about Biodexa Pharmaceuticals
When was Biodexa Pharmaceuticals founded?
Biodexa Pharmaceuticals was founded in 2000 and raised its 1st funding round 23 years after it was founded.
Where is Biodexa Pharmaceuticals located?
Biodexa Pharmaceuticals is headquartered in Cardiff, United Kingdom. It is registered at Cardiff, Wales, United Kingdom.
Who is the current CEO of Biodexa Pharmaceuticals?
Stephen Stamp is the current CEO of Biodexa Pharmaceuticals.
Is Biodexa Pharmaceuticals a funded company?
Biodexa Pharmaceuticals is a funded company, having raised a total of $6.79M across 1 funding round to date. The company's 1st funding round was a Series A of $6.79M, raised on Dec 21, 2023.
What does Biodexa Pharmaceuticals do?
Biodexa Pharmaceuticals was founded in 2000 and is based in Cardiff, United Kingdom. Focus is placed on the pharmaceutical sector, where therapeutics for brain cancer treatment are developed. The lead candidate, MTX110, consists of a solubilised formulation of the histone deacetylase inhibitor panobinostat. This is targeted at recurrent glioblastoma, medulloblastoma, and paediatric diffuse midline glioma, addressing rare and orphan indications in oncology.
Who are the top competitors of Biodexa Pharmaceuticals?
Biodexa Pharmaceuticals's top competitors include Modifi Bio, OncoSynergy and Flag Therapeutics.
What products or services does Biodexa Pharmaceuticals offer?
Biodexa Pharmaceuticals offers eRapa, Tolimidone, and MTX110.